BACKGROUND: Vaccination against pertussis during pregnancy is recommended to protect newborns, yet there is limited information about the effectiveness of maternal tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap) vaccine before the first infant dose of diphtheria, tetanus and acellular pertussis (DTaP) vaccine and during the first year of life in infants who have received DTaP. METHODS: In a retrospective cohort study of infants born at Kaiser Permanente Northern California from 2010 to 2015, we estimated the effectiveness of maternal pertussis vaccination for protecting newborns against pertussis in the first 2 months of life and in the first year of life accounting for each infant DTaP dose. RESULTS: Among 148 981 newborns, the vaccine effectiveness of maternal Tdap was 91.4% (95% confidence interval [CI], 19.5 to 99.1) during the first 2 months of life and 69.0% (95% CI, 43.6 to 82.9) during the entire first year of life. The vaccine effectiveness was 87.9% (95% CI, 41.4 to 97.5) before infants had any DTaP vaccine doses, 81.4% (95% CI, 42.5 to 94.0) between doses 1 and 2, 6.4% (95% CI, -165.1 to 66.9) between doses 2 and 3, and 65.9% (95% CI, 4.5 to 87.8) after infants had 3 DTaP doses. CONCLUSIONS: Maternal Tdap vaccination was highly protective against infant pertussis, especially in the first 2 months of life. Even after infant DTaP dosing, there was evidence of additional protection from maternal Tdap vaccination for the first year of life. This study strongly supports the United States' current recommendation to administer Tdap during each pregnancy.
BACKGROUND: Vaccination against pertussis during pregnancy is recommended to protect newborns, yet there is limited information about the effectiveness of maternal tetanus toxoid, reduced diphtheria toxoid, acellular pertussis (Tdap) vaccine before the first infant dose of diphtheria, tetanus and acellular pertussis (DTaP) vaccine and during the first year of life in infants who have received DTaP. METHODS: In a retrospective cohort study of infants born at Kaiser Permanente Northern California from 2010 to 2015, we estimated the effectiveness of maternal pertussis vaccination for protecting newborns against pertussis in the first 2 months of life and in the first year of life accounting for each infantDTaP dose. RESULTS: Among 148 981 newborns, the vaccine effectiveness of maternal Tdap was 91.4% (95% confidence interval [CI], 19.5 to 99.1) during the first 2 months of life and 69.0% (95% CI, 43.6 to 82.9) during the entire first year of life. The vaccine effectiveness was 87.9% (95% CI, 41.4 to 97.5) before infants had any DTaP vaccine doses, 81.4% (95% CI, 42.5 to 94.0) between doses 1 and 2, 6.4% (95% CI, -165.1 to 66.9) between doses 2 and 3, and 65.9% (95% CI, 4.5 to 87.8) after infants had 3 DTaP doses. CONCLUSIONS: Maternal Tdap vaccination was highly protective against infant pertussis, especially in the first 2 months of life. Even after infantDTaP dosing, there was evidence of additional protection from maternal Tdap vaccination for the first year of life. This study strongly supports the United States' current recommendation to administer Tdap during each pregnancy.
Authors: Nicholas Brousseau; Dominique Gagnon; Maryline Vivion; Vanessa Poliquin; Isabelle Boucoiran; Bruce Tapiéro; Eve Dubé Journal: CMAJ Open Date: 2018-09-20
Authors: Ousseny Zerbo; G Thomas Ray; Lea Zhang; Kristin Goddard; Bruce Fireman; Alyce Adams; Saad Omer; Martin Kulldorff; Nicola P Klein Journal: Am J Epidemiol Date: 2020-11-02 Impact factor: 4.897
Authors: Elinor Willis; Norbert Pardi; Kaela Parkhouse; Barbara L Mui; Ying K Tam; Drew Weissman; Scott E Hensley Journal: Sci Transl Med Date: 2020-01-08 Impact factor: 17.956
Authors: Bhavita Vishram; Louise Letley; Albert Jan Van Hoek; Louise Silverton; Helen Donovan; Cheryll Adams; David Green; Angela Edwards; Joanne Yarwood; Helen Bedford; Gayatri Amirthalingam; Helen Campbell Journal: Hum Vaccin Immunother Date: 2017-11-27 Impact factor: 3.452
Authors: Sylvia Becker-Dreps; Anne M Butler; Leah J McGrath; Kim A Boggess; David J Weber; Dongmei Li; Michael G Hudgens; J Bradley Layton Journal: Am J Prev Med Date: 2018-06-14 Impact factor: 5.043